Skip to main content

Advertisement

SpringerLink
Log in

MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer

  • Research
  • Published:
Pathology & Oncology Research

Abstract

MUC1 expression has been described as a predictor for tumor progression and worsening of prognosis in various human neoplasms. However, little is known about the role of MUC1 expression in pulmonary metastatic tumors. The aim of this study is to examine the clinicopathological significance of MUC1 expression in pulmonary metastatic tumors (PMT). One hundred forty-seven patients with PMT who underwent 18F-FDG PET before metastasectomy were included in this study. Tumor sections were stained by immunohistochemistry for MUC1, glucose transporter 1 (Glut1), hypoxia-inducible-1α (HIF-1α) and vascular endothelial growth factor (VEGF). 18F-FDG uptake and the expression of these biomarkers were correlated in primary lung cancer. MUC1 expression pattern was classified into high-grade polarized expression (HP), low-grade polarized expression (LP), or depolarized expression (DP) group. Of 147 patients, HP, LP and DP group were 9 (6%), 114 (78%) and 24 (16%), respectively. The expression of Glut1, HIF-1αand VEGF, and 18F-FDG uptake were significantly higher in DP group than HP or LP groups. MUC1 expression with HP and DP pattern was significantly higher in primary lung cancer than in PMT, whereas, MUC1 expression with LP pattern yielded a significantly high positive rate in PMT. LP group was recognized in the majority of patients with pulmonary metastatic adenocarcinoma, especially colon cancer, whereas, HP group was significantly low in pulmonary metastatic adenocarcinoma as compared with primary adenocarcinoma. Polarized MUC1 has a different expression pattern between primary and metastatic tumors with adenocarcinoma, and depolarized MUC1 is closely associated with glucose metabolism and hypoxia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286–15293

    PubMed  CAS  Google Scholar 

  2. Schroeder JA, Masril AA, Adriance MC et al (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23:5739–5747

    Article  PubMed  CAS  Google Scholar 

  3. Nagai S, Takenaka K, Sonobe M et al (2006) A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 1:46–51

    Article  PubMed  Google Scholar 

  4. Woenckhaus M, Merk J, Stoehr R et al (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39:126–136

    Article  PubMed  CAS  Google Scholar 

  5. Utsunomiya T, Yonezawa S, Sakamoto H et al (1998) Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4:2605–2614

    PubMed  CAS  Google Scholar 

  6. Hinoda Y, Ikematsu Y, Horinouchi M et al (2003) Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 38:1162–1166

    Article  PubMed  CAS  Google Scholar 

  7. Tamada S, Goto M, Nomoto M et al (2002) Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 52:713–723

    Article  PubMed  Google Scholar 

  8. Kawamoto T, Shoda J, Miyahara N et al (2004) Expression of MUC1 recognized by a monoclonal antibody MY. 1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis 21:353–362

    Article  PubMed  CAS  Google Scholar 

  9. Feng H, Ghazizadeh M, Konishi H et al (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32:525–529

    Article  PubMed  Google Scholar 

  10. Sivridis E, Giatromanolaki A, Koukourakis MI et al (2002) Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology 40:92–100

    Article  PubMed  CAS  Google Scholar 

  11. Baldus SE, Monig SP, Huxel S et al (2004) MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10:2790–2796

    Article  PubMed  CAS  Google Scholar 

  12. Kirschenbaum A, Itzkowitz SH, Wang JP et al (1999) MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 3:163–168

    PubMed  Google Scholar 

  13. Broadbent R, Thynne G, McKenzie IFC (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783–2792

    Article  PubMed  Google Scholar 

  14. Hirasawa Y, Kohno N, Yokoyama A et al (2000) Natural antoantobody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 16:589–594

    Google Scholar 

  15. Giatromanolaki A, Koukourakis MI, Sivridis E et al (2000) Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 6:1917–1921

    PubMed  CAS  Google Scholar 

  16. Situ D, Wang J, Ma Y, et al (2010) Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol Nov 30 [Epub ahead of print]

  17. Kaira K, Okumura T, Ohde Y et al (2011) Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med 52:705–711

    Article  PubMed  Google Scholar 

  18. Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753

    Article  PubMed  CAS  Google Scholar 

  19. Mikami Y, Hisatsune A, Tashiro T et al (2009) Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun 379:1060–1065

    Article  PubMed  CAS  Google Scholar 

  20. Aubert S, Fauquette V, Hémon B et al (2009) MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 69:5707–5715

    Article  PubMed  CAS  Google Scholar 

  21. Kontani K, Taguchi O, Ozaki Y et al (2003) Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucins. Int J Mol Med 12:493–502

    PubMed  CAS  Google Scholar 

  22. Kufe DW (2009) Functional targeting of MUC1 oncogene in human cancers. Cancer Biol Ther 8:1197–1203

    PubMed  CAS  Google Scholar 

Download references

Conflicts of Interest Statement

We, all authors, have no financial or personal relationships with other people or organizations that could inappropriately influence our work.

Author information

Authors and Affiliations

  1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan

    Kyoichi Kaira, Toshiaki Takahashi, Haruyasu Murakami, Tateaki Naito & Nobuyuki Yamamoto

  2. Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan

    Takehiro Okumura, Kazuo Nakagawa, Yasuhisa Ohde & Haruhiko Kondo

  3. Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan

    Masahiro Endo

  4. Division of Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan

    Takashi Nakajima

Authors
  1. Kyoichi Kaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takehiro Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuo Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhisa Ohde
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haruyasu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tateaki Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiro Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Haruhiko Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nobuyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyoichi Kaira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaira, K., Okumura, T., Nakagawa, K. et al. MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer. Pathol. Oncol. Res. 18, 439–447 (2012). https://doi.org/10.1007/s12253-011-9465-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9465-9

Keywords

Search

Navigation